Type 2 Diabetes Mellitus and the Catabolic Response to Surgery

Thomas Schricker, M.D., Ph.D.,* Rejeanne Gougeon, Ph.D.,† Leopold Eberhart, M.D., Ph.D.,‡ Linda Wykes, Ph.D.,§ Louise Mazza, B.Sc., George Carvalho, M.D., B.Sc., Franco Carli, M.D., M.Phil.**

Background: The authors tested the hypothesis that the catabolic responses to colorectal surgery are amplified in the presence of type 2 diabetes mellitus.

Methods: Seven nondiabetic and seven diabetic patients underwent a 6-h stable isotope infusion study (3 h fasted, 3-h glucose infusion at 4 mg · kg⁻¹ · min⁻¹) on the second postoperative day. Leucine rate of appearance (Rₑ), leucine oxidation, nonoxidative leucine disposal, and glucose Rₑ were assessed by L-[1-¹³C]leucine and [6,6-²H₂]glucose. Circulating concentrations of glucose, lactate, insulin, glucagon, and cortisol also were determined.

Results: Diabetic patients had a higher leucine oxidation than nondiabetic patients (P = 0.0003), whereas leucine Rₑ and nonoxidative leucine disposal were not different. Administration of glucose did not affect leucine kinetics regardless of whether patients were diabetic. In diabetic patients, glucose Rₑ was greater than in the nondiabetic group (P = 0.0032). Glucose infusion suppressed the endogenous glucose Rₑ to a lesser extent in diabetic than in nondiabetic patients (P = 0.0048). Plasma glucose concentrations were higher in diabetic than in nondiabetic patients (P = 0.0203), both in the postabsorptive and the fed state. Circulating concentrations of glucagon were higher (P = 0.0065) and concentrations of insulin were lower (P = 0.0146) in the presence of diabetes, resulting in a lower insulin/glucagon ratio (P = 0.0002). In diabetic patients, the insulin/glucagon ratio increased during glucose infusion to a lesser extent than in the nondiabetic group (P = 0.0014).

Conclusion: Protein catabolism after colorectal surgery is increased in patients with type 2 diabetes mellitus as reflected by an increased oxidative protein loss.

THE endocrine response to surgical tissue trauma is characterized by the activation of the hypothalamic-pituitary and sympathoadrenergic system, resulting in increased circulating concentrations of cortisol, glucagon, epinephrine, and norepinephrine. All these hormones inhibit insulin secretion and/or counteract the peripheral action of insulin, leading to a state of impaired tissue insulin sensitivity. Insulin resistance is thought to be one of the principal mechanisms responsible for the catabolic responses to surgery, including stimulated amino acid oxidation, muscle proteolysis, and glucose-ogenesis along with decreased glucose utilization and hyperglycemia. The similarity between the metabolic changes associated with surgery and those typically observed in patients with type 2 diabetes mellitus gave rise to the term diabetes of injury. It also has been suggested that the catabolic responses to surgery are augmented in type 2 diabetic patients. However, there is little evidence to substantiate this assumption. Whereas hyperglycemia after cataract surgery was more pronounced, the metabolic and endocrine alterations after major abdominal surgical procedures have never been evaluated in patients with type 2 diabetes mellitus.

The goal of the current study was to examine postoperative protein and glucose catabolism during fasting conditions and during a 3-h infusion of 4 mg · kg⁻¹ · min⁻¹ glucose in diabetic and nondiabetic patients undergoing colorectal surgery, the hypothesis being that the catabolic responses are amplified in the presence of type 2 diabetes mellitus.

Materials and Methods

Patients

With the approval of the Ethics Committee of the Royal Victoria Hospital (Montreal, Quebec, Canada), informed consent was obtained from seven patients with type 2 diabetes mellitus and seven nondiabetic patients. All patients had localized nonmetastatic adenocarcinoma of the rectosigmoid colon and were scheduled to undergo elective colorectal surgery. None of the patients had cardiac, hepatic, or renal disease. No subject had developed recent weight loss or had an albumin concentration below 35 g/l. Diabetes treatment included diet alone (n = 2), glyburide (n = 3; 2 patients, 10 mg/day; 1 patient, 5 mg/day), and glyburide (10 mg/day) combined with metformin (1,000 mg/day; n = 2). Diabetic subjects had been diagnosed with diabetes mellitus for an average of 6 ± 2 yr (mean ± SD). All patients, except two whose glucose values were 8.2 and 7.4 mm on hospital admission, had normal postabsorptive plasma glucose concentrations as determined on two occasions after overnight fasting before the operation.

Surgical and Anesthesia Care

The patients were prepared for surgery in a standardized fashion. Solid food intake stopped after breakfast the day before surgery, and only clear liquids were allowed until 22:00. All operations were performed by the same surgeon and at the same time of the day (between...
08:00 and 12:00). Anesthesia was standardized and performed by the same anesthesiologist (T. S.). All patients received intraoperative epidural anesthesia combined with general anesthesia. General anesthesia was induced with intravenous thiopentone and maintained with 35% nitrous oxide in oxygen and isoflurane. Epidural catheters were inserted before induction of general anesthesia between T9 and T11. Bupivacaine, 0.5% (15–20 ml), was injected to produce a confirmed bilateral segmental sensory block from T4 to L2. Additional 0.25% bupivacaine (5–10 ml) was injected 1–2 h later. At the end of surgery, 0.1% epidural bupivacaine supplemented with 2 μg/ml fentanyl was administered continuously at a rate of 10–15 ml/h and maintained for at least 48 h. The segmental sensory level of analgesia was assessed twice a day using a blunted needle and ice, and the infusion was adjusted to maintain a bilateral sensory block between T7 and L2. Pain treatment in both groups was adjusted to obtain a visual analog scale score of less than 4 at rest (visual analogue scale from 0 = no pain to 10 = worst pain imaginable).

All patients received hypocaloric nutritional supplementation with glucose from 08:00 to 20:00 on the first postoperative day (100 ml/h glucose, 5%) followed by infusion of 0.9% sodium chloride (100 ml/h) until the study period. No patient received insulin treatment postoperatively unless the blood glucose concentration as determined every 8 h exceeded 10 mm.

**Experimental Protocol**

All tests were performed in the fasted state beginning at 08:00 in the morning of the second day after surgery. After a 3-h period of fasting, a solution of crystalized beet sugar (10% dextrose anhydrous; Avebe, Foxhol, Holland) was infused at 4 mg · kg⁻¹ · min⁻¹ L-[1-¹³C]leucine lasting 6 h. [6,6-²H₂]glucose was infused at a rate of 0.22 μmol · kg⁻¹ · min⁻¹ during the first 3 h (fasted period) and then changed to 0.44 μmol · kg⁻¹ · min⁻¹ during the 3 h of glucose administration. Toward the end of each 3-h study period, four blood and expired breath samples were collected at 10-min intervals. Each blood sample was transferred immediately to a heparinized tube, centrifuged at 4°C (3,000g, 15 min) and stored at −70°C. Breath samples were collected in a 2-l latex bag and transferred immediately to 20-ml vacutainers.

**Gaseous Exchange**

Indirect calorimetry (Datex Deltatrac, Helsinki, Finland) was performed in the last hour of the fasted state and toward the end of the glucose infusion period. The subjects were lying in a semirecumbent position (20°), breathing room air in the ventilated hood. Oxygen consumption and carbon dioxide production were measured. The values of oxygen consumption, carbon dioxide production, and respiratory quotient represent an average of the data obtained during a 20-min period on each occasion, with a coefficient of variation less than 10%. Energy expenditure and respiratory quotient were calculated. Carbohydrate and lipid oxidation rates were calculated using standard formulas.⁹ Protein oxidation was calculated using the measured rate of leucine oxidation and assuming that leucine represents 8% of total body protein.¹⁰

**Isotopic Enrichments**

Plasma [1-¹³C]ketoisocaproate enrichment was determined by electron impact selected-ion monitoring gas chromatography–mass spectrometry using the method described by Mamer and Montgomery,¹¹ except that the t-butyldimethylsylyl rather than trimethylsylyl derivative was prepared. Expired ¹³C-carbon dioxide enrichment was determined by isotope ratio mass spectrometry (Analytical Precision AP2003, Manchester, United Kingdom).¹² Plasma glucose was derivatized to its pentacetate compound, and the [6,6-²H₂]glucose enrichment was determined by gas chromatography–mass spectrometry using electron impact ionization.¹² In each analysis run, duplicate injections were always performed, and their means were taken to represent enrichment.
agnostics, Dublin, Ireland). Circulating concentrations of insulin and glucagon were measured by sensitive and specific double antibody radioimmunoassays (Linco Research Inc., Palo Alto, CA).\textsuperscript{15}

**Calculations**

When a physiologic and isotopic steady state exists, the rate of appearance (R\textsubscript{a}) of unlabeled substrate in plasma can be derived from the plasma isotope enrichment (atom percentage excess [APE]) calculated by

\[ R_a = (\text{APE}_{\text{inf}}/\text{APE}_{\text{pl}} - 1) \cdot F, \]

where F is the infusion rate of the labeled tracer, APE\textsubscript{inf} is the tracer enrichment in the infusate, and APE\textsubscript{pl} is the tracer enrichment in plasma, respectively. The APE values used in this calculation were the mean of the four APE values determined during steady state conditions obtained at each phase of the studies. The accuracy of the isotopic enrichments at isotopic plateau was tested by evaluating the scatter of values above their mean, expressed as coefficient of variation. A coefficient of variation of less than 5\% was used as a confirmation of a valid plateau.

During steady state conditions, leucine flux (Q) is defined by the formula

\[ Q = S + O = B + I, \]

where S is the rate at which leucine is incorporated into body protein, O is the rate of oxidation of leucine, B is the rate at which unlabeled leucine enters the free amino acid pool from endogenous protein breakdown, and I is the rate of leucine intake including tracer and diet. In the postabsorptive state, the sole source of the essential amino acid leucine for protein synthesis and oxidation is that derived from the breakdown of endogenous proteins. Plasma enrichment of [1\textsuperscript{13}C]ketoisocaproate was used as the basis for calculating both flux and oxidation of leucine.\textsuperscript{14} In the calculation of oxidation, factors of 0.76 for the fasting state and 0.81 during glucose infusion were applied to account for the fraction of \textsuperscript{13}C-carbon dioxide released from leucine but retained within slow turnover rate pools of the body.\textsuperscript{10,12,15}

In the fasted state, R\textsubscript{glucose} was equal to the endogenous production of glucose. During glucose infusion, endogenous glucose production was calculated by subtracting the glucose infusion rate from the total R\textsubscript{glucose}. The plasma glucose clearance rate was calculated as R\textsubscript{glucose} divided by the corresponding plasma glucose concentration.

**Control Group**

A small control group with three type 2 diabetic patients (two male, one female) who had adenocarcinoma of the colon was also studied. Diabetes treatment included diet alone (n = 1) or glyburide (n = 2; 10 mg/day) and none of the patients had cardiac, hepatic, or renal disease. Postabsorptive circulating albumin and glucose concentrations before the study were normal in all three subjects. Patients were prepared for surgery in the same standardized fashion as patients in the two study groups. Using the methods described above, leucine and glucose kinetics, circulating concentrations of metabolic substrate, and hormones as well as gaseous exchange were measured during postabsorptive conditions only, i.e., no glucose was administered. Isotope infusions were performed over 3 h starting 4 h before the operation. Values were compared to results obtained in nondiabetic patients studied during the same conditions.\textsuperscript{16}

**Statistics**

The primary endpoint of the study was leucine oxidation. On the basis of our previous studies, a difference of mean leucine oxidation of at least 4 \(\mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}\) between the two patient groups (between group effect) and between the two feeding states (within-group effect) was defined as metabolically relevant.\textsuperscript{12} Assuming an SD as obtained previously, a repeated-measure design with two times seven patients achieves a power of 70\% to detect a between-group effect size of 0.72 and a power of 99\% to detect the within-group effect size of 0.88 with a type I error of 5\%. This prospective power analysis was performed with PASS 2002 (Number Cruncher Statistical Systems, Kaysville, UT).

Analyses of variables were performed using two-factorial analysis of variance for repeated measures. If no significant change was detected between the two measurements (glucose, lactate, cortisol, insulin, glucagon) after 150 and 180 min of glucose infusion, the average values were compared with the one value determined before glucose administration. Significant effects induced by glucose administration were assumed when \(p\) values for time dependency were less than 0.05. Influences by diabetes were accepted as significant when the interaction term of the analysis of variance was below 0.05. All analyses were performed using the General Linear Model in SPSS 11.0 for Windows (SPSS Inc., Chicago, IL).

**Results**

**Patients**

There were no differences between the two groups regarding sex, age, or body mass index of patients (table 1). Estimated blood loss never exceeded 400 ml, and no patient received a blood transfusion. No patient required insulin treatment in the postoperative course.

**Leucine and Glucose Kinetics**

In all experiments, a plateau in the enrichments of plasma [1\textsuperscript{13}C]ketoisocaproate, [6,6\textsuperscript{2}H\textsubscript{2}]glucose, and \textsuperscript{13}C-carbon dioxide was achieved (coefficient of varia-
tion < 5%), permitting the use of the steady state equation. Diabetic patients had a higher leucine rate of oxidation than nondiabetic patients (P = 0.0003), whereas leucine Ra and nonoxidative leucine disposal were not different (table 2). Administration of glucose had no significant effect on leucine kinetics regardless of whether patients were diabetic (table 2). In diabetic patients, the postabsorptive endogenous and total glucose Ra were greater than in the nondiabetic group (P = 0.0052; table 2). Glucose infusion suppressed the endogenous Ra to a lesser extent in diabetic than in nondiabetic patients (P = 0.0048; table 2). In the nondiabetic group, glucose clearance during glucose feeding was higher than in diabetic patients (P = 0.0007; table 2).

Metabolic Substrates and Hormones
Plasma glucose concentrations were significantly higher in diabetic than in nondiabetic patients (P = 0.0203), both in the postabsorptive state and during the administration of glucose (table 3). Circulating concentrations of glucagon were higher (P = 0.0065) and circulating concentrations of insulin were lower (P = 0.0146) in patients with diabetes, resulting in a lower insulin/glucagon ratio (P = 0.0002; table 3). In diabetic patients, the insulin/glucagon ratio increased during glucose infusion to a lesser extent than in the nondiabetic group (P = 0.0014; table 3). Significant negative correlations between the Ra glucose and the insulin/glucagon ratio (r² = 0.175, P = 0.028) and between protein oxidation and insulin/glucagon ratio were observed (r² = 0.186, P = 0.022).

Gaseous Exchange
In the fasted state, oxygen consumption (P = 0.0417), protein oxidation (P = 0.0006), and lipid oxidation (P = 0.0549) were higher, whereas carbohydrate oxidation was lower in diabetic (P = 0.0170) compared with nondiabetic patients (table 4). During the administration of glucose, the respiratory quotient (P = 0.0288) increased and lipid oxidation (P = 0.0172) decreased in the two groups (table 4).

Control Group
Values obtained in the small control group of diabetic patients studied before surgery for colorectal cancer indicate that leucine oxidation, protein oxidation, and leucine rate of appearance are not increased when compared with nondiabetic patients with colorectal cancer who were preoperatively studied during identical conditions (table 5). Circulating concentrations of glucose and lipid oxidation rates seem to be increased, whereas circulating insulin concentrations and carbohydrate oxidation rates seem to be lower in diabetic patients (table 5).

Table 1. Characteristics of the Patients

<table>
<thead>
<tr>
<th></th>
<th>Nondiabetic Patients</th>
<th>Diabetic Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n, female:male</td>
<td>4:3</td>
<td>3:4</td>
</tr>
<tr>
<td>Age, yr</td>
<td>60 ± 13</td>
<td>56 ± 22</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23 ± 3</td>
<td>23 ± 4</td>
</tr>
<tr>
<td>Surgery, n</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colectomy</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Left hemicolectomy</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Low anterior resection</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Duration of surgery, min</td>
<td>205 ± 84</td>
<td>214 ± 57</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD.
BMI = body mass index.

Table 2. Leucine and Glucose Kinetics

<table>
<thead>
<tr>
<th></th>
<th>Nondiabetic Patients</th>
<th>Diabetic Patients</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fasted</td>
<td>Glucose</td>
<td>Fasted</td>
</tr>
<tr>
<td>Leucine rate of appearance, μmol·kg⁻¹·h⁻¹</td>
<td>116 ± 29</td>
<td>113 ± 30</td>
<td>133 ± 26</td>
</tr>
<tr>
<td>Leucine oxidation, μmol·kg⁻¹·h⁻¹</td>
<td>20 ± 4</td>
<td>17 ± 5</td>
<td>29 ± 9</td>
</tr>
<tr>
<td>Nonoxidative leucine disposal, μmol·kg⁻¹·h⁻¹</td>
<td>96 ± 26</td>
<td>96 ± 37</td>
<td>104 ± 21</td>
</tr>
<tr>
<td>Glucose rate of appearance, μmol·kg⁻¹·min⁻¹</td>
<td>9.8 ± 1.6</td>
<td>23.2 ± 2.6</td>
<td>15.3 ± 2.1</td>
</tr>
<tr>
<td>Endogenous glucose rate of appearance, μmol·kg⁻¹·min⁻¹</td>
<td>9.8 ± 1.6</td>
<td>1.6 ± 1.6</td>
<td>15.3 ± 2.1</td>
</tr>
<tr>
<td>Glucose clearance, ml·kg⁻¹·min⁻¹</td>
<td>2.0 ± 0.3</td>
<td>2.4 ± 0.4</td>
<td>2.1 ± 0.5</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD.
* Probability that values are influenced by intravenous glucose. † Probability that values are influenced by diabetes regardless of whether glucose was administered. ‡ Probability that the effect of glucose is greater in one distinct group.
Lipid oxidation, g/d 102
Carbohydrate oxidation, g/d 40
Protein oxidation, g/d 52
Respiratory quotient 0.76

surgery from those induced by diabetes mellitus observed postoperatively only. Hence, our study design by insulin 23 in type 2 diabetic patients under good or

sence of injury.5 Patients in the present protocol werestrate signs of an acute-phase response even in the ab-

Values are presented as mean ± SD.
* Probability that values are influenced by intravenous glucose. † Probability that values are influenced by diabetes regardless of whether glucose was administered. ‡ Probability that the effect of glucose is greater in one distinct group.

### Discussion

The results of this study indicate that the catabolic responses to colorectal surgery are increased in patients with type 2 diabetes mellitus as reflected by a 50% greater amino acid oxidation, glucose production, and glucose plasma concentration compared with nondiabetic patients during fasting conditions. Administration of glucose inhibited endogenous glucose production to a lesser extent in diabetic than in nondiabetic patients. These findings lend further support to the previous assumption that type 2 diabetes mellitus accentuates the metabolic abnormalities produced by surgical tissue trauma; combined infusions of epinephrine, cortisol, and glucagon have been shown to cause a greater hyperglycemic response in diabetic subjects than in healthy volunteers 17. Others have also shown that after minor surgery, glucose plasma concentrations were increased to a greater extent in type 2 diabetic patients, 7 who demonstrate signs of an acute-phase response even in the absence of injury.5 Patients in the present protocol were observed postoperatively only. Hence, our study design does not allow us to dissect the metabolic effects of surgery from those induced by diabetes mellitus per se.

Insulin deficiency can be associated with increased protein breakdown and oxidation as seen during type 1 diabetes mellitus. 18,19 The rate of leucine appearances 20–22 as well as the inhibition of protein breakdown by insulin 25 in type 2 diabetic patients under good or moderate glucose control, however, seems to be normal. In poorly controlled and obese type 2 diabetic subjects, protein breakdown as assessed by the [15N]glycine method was increased as compared with a nondiabetic, weight-matched control group. 24,25 Except for two studies involving poorly controlled type 2 diabetic populations, 5,21 no studies have demonstrated increased leucine oxidation in diabetic patients. Although the majority of studies suggest that type 2 diabetes mellitus does not alter amino acid kinetics, 20,22,26 no information is available in patients with diabetes and colorectal cancer. Leucine appearance and oxidation in subjects with poorly controlled type 2 diabetes studied after a 10-h overnight fast were not significantly different from values observed in nondiabetic patients with lung cancer. 5 The results obtained in our small control group of patients before surgery also indicate that protein oxidation and breakdown are not increased in diabetic patients with colorectal cancer when compared with nondiabetic subjects.

It has long been recognized that type 2 diabetes mellitus leads to a moderate increase in glucose production and gluconeogenesis during postabsorptive conditions. 5,21,27,28 Increased glucose production rates have also been reported in well-nourished patients with malignant disease. 29,30 Glucose production rates in type 2 diabetic patients and nondiabetic subjects with cancer were increased to a similar extent as compared to

Table 3. Circulating Concentrations of Metabolites and Hormones

<table>
<thead>
<tr>
<th>Glucose, mM</th>
<th>Fasted</th>
<th>Glucose</th>
<th>Fasted</th>
<th>Glucose</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose*</td>
<td>5.0 ± 0.5</td>
<td>10.0 ± 0.8</td>
<td>7.6 ± 2.4</td>
<td>14.3 ± 4.5</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Lactate, mM</td>
<td>1.0 ± 0.2</td>
<td>1.0 ± 0.2</td>
<td>1.2 ± 0.3</td>
<td>1.2 ± 0.3</td>
<td>0.3284</td>
</tr>
<tr>
<td>Cortisol, nM</td>
<td>446 ± 201</td>
<td>323 ± 139</td>
<td>380 ± 83</td>
<td>289 ± 109</td>
<td>0.3870</td>
</tr>
<tr>
<td>Insulin, pM</td>
<td>102 ± 18</td>
<td>328 ± 148</td>
<td>80 ± 46</td>
<td>160 ± 96</td>
<td>0.0011</td>
</tr>
<tr>
<td>Glucagon, pM</td>
<td>27 ± 5</td>
<td>17 ± 5</td>
<td>41 ± 16</td>
<td>28 ± 13</td>
<td>0.0190</td>
</tr>
<tr>
<td>Insulin/glucagon</td>
<td>4 ± 1</td>
<td>21 ± 6</td>
<td>2 ± 1</td>
<td>6 ± 3</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

Table 4. Gaseous Exchange

<table>
<thead>
<tr>
<th>Glucose*</th>
<th>Diabetes†</th>
<th>Interaction‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen consumption, ml/min</td>
<td>Fasted</td>
<td>200 ± 32</td>
</tr>
<tr>
<td>Carbon dioxide production, ml/min</td>
<td>151 ± 19</td>
<td>158 ± 32</td>
</tr>
<tr>
<td>Respiratory quotient</td>
<td>0.76 ± 0.03</td>
<td>0.81 ± 0.04</td>
</tr>
<tr>
<td>Protein oxidation, g/d</td>
<td>52 ± 16</td>
<td>43 ± 17</td>
</tr>
<tr>
<td>Carbohydrate oxidation, g/d</td>
<td>40 ± 32</td>
<td>109 ± 61</td>
</tr>
<tr>
<td>Lipid oxidation, g/d</td>
<td>102 ± 32</td>
<td>78 ± 23</td>
</tr>
</tbody>
</table>

Values are presented as mean ± SD.
* Probability that values are influenced by intravenous glucose. † Probability that values are influenced by diabetes regardless of whether glucose was administered. ‡ Probability that the effect of glucose is greater in one distinct group.
healthy volunteers. The effect of diabetes mellitus on glucose kinetics in patients with intestinal cancer is unknown. The findings in our control patients, however, seem to demonstrate that postabsorptive glucose production rates and circulating glucose concentrations are increased, whereas carbohydrate oxidation is decreased in the presence of diabetes and colorectal carcinoma.

Administration of glucose in the current study did not affect the leucine rate of appearance and oxidation regardless of whether patients were diabetic. This finding is consistent with observations in healthy subjects and surgical patients showing that the infusion of glucose at rates increasing the circulating insulin concentration to a level similar to that in the current protocol does not influence protein breakdown and amino acid oxidation. In contrast, administration of insulin resulting in circulating insulin concentrations greater than 150 mIU/ml blocks the release of muscle amino-nitrogen, whereas insulin clamped at a serum level of 80 mIU/ml induces a decrease in whole body leucine release.

The inhibitory effect of exogenous glucose on endogenous glucose production has been shown to depend on the dose of glucose infused and the physiologic state of the subject. Glucose administered at 4 mg · kg⁻¹ · min⁻¹ almost completely suppresses endogenous glucose production in healthy volunteers, whereas glucose applied at the same rate in patients after trauma and during sepsis diminishes glucose production by 50% only.

In the current study, the inhibitory action of glucose on the endogenous rate of appearance was less pronounced in diabetic than in nondiabetic patients. In addition, during glucose administration, the glucose clearance and carbohydrate oxidation were less in the presence of diabetes. This is in accordance with the limited suppressibility of endogenous glucose production and abnormal peripheral glucose utilization typically observed in diabetes mellitus. Thus, the ability of ambient glucose at moderately increased circulating insulin concentrations to regulate glucose metabolism was impaired in the current group of diabetic patients. This defect involves both blunted inhibition of endogenous glucose production and decreased stimulation of glucose uptake and oxidation.

Because the current study was not designed to identify the biochemical factors causing the discrepancy between the catabolic responses in diabetic and nondiabetic patients, we can only speculate about the underlying mechanisms. Lower circulating insulin concentrations accompanied by greater circulating glucagon concentrations in the diabetic group and negative correlations between the insulin/glucagon ratio and glucose production as well as protein oxidation suggest that changes in the insulin/glucagon ratio, indicates that other mechanisms, including alterations in the sympathoadrenergic or inflammatory system, may have contributed.

We acknowledge several limitations of this study. Before surgery, hemoglobin A₁c concentrations were not determined in the diabetic patient population. Although

---

**Table 5. Control Group**

<table>
<thead>
<tr>
<th></th>
<th>Diabetic Patients</th>
<th></th>
<th>Nondiabetic Patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td>Age, yr</td>
<td>67</td>
<td>71</td>
<td>66</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.9</td>
<td>26.6</td>
<td>29.1</td>
</tr>
<tr>
<td>Leucine rate of appearance, μmol · kg⁻¹ · h⁻¹</td>
<td>108</td>
<td>120</td>
<td>103</td>
</tr>
<tr>
<td>Leucine oxidation, μmol · kg⁻¹ · h⁻¹</td>
<td>22</td>
<td>19</td>
<td>14</td>
</tr>
<tr>
<td>Nonoxidative leucine disposal, μmol · kg⁻¹ · h⁻¹</td>
<td>86</td>
<td>101</td>
<td>89</td>
</tr>
<tr>
<td>Glucose rate of appearance, μmol · kg⁻¹ · min⁻¹</td>
<td>12.7</td>
<td>13.3</td>
<td>15.3</td>
</tr>
<tr>
<td>Glucose, mM</td>
<td>6.8</td>
<td>5.4</td>
<td>8.7</td>
</tr>
<tr>
<td>Lactate, mM</td>
<td>1.2</td>
<td>0.8</td>
<td>1.0</td>
</tr>
<tr>
<td>Cortisol, nm</td>
<td>153</td>
<td>350</td>
<td>200</td>
</tr>
<tr>
<td>Insulin, pM</td>
<td>22</td>
<td>45</td>
<td>30</td>
</tr>
<tr>
<td>Glucagon, pM</td>
<td>22</td>
<td>22</td>
<td>13</td>
</tr>
<tr>
<td>Insulin/glucagon</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Oxygen consumption, ml/min</td>
<td>265</td>
<td>208</td>
<td>225</td>
</tr>
<tr>
<td>Carbon dioxide production, ml/min</td>
<td>195</td>
<td>157</td>
<td>173</td>
</tr>
<tr>
<td>Respiratory quotient</td>
<td>0.74</td>
<td>0.75</td>
<td>0.77</td>
</tr>
<tr>
<td>Protein oxidation, g/d</td>
<td>80</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>Carbohydrate oxidation, g/d</td>
<td>16</td>
<td>42</td>
<td>73</td>
</tr>
<tr>
<td>Lipid oxidation, g/d</td>
<td>144</td>
<td>106</td>
<td>111</td>
</tr>
</tbody>
</table>

*Reference values are the mean of 12 nondiabetic patients (5 male, 7 female) studied under the same conditions and published previously. BMI = body mass index.
likely indicates an increased catabolic response to sur-
tive resections of colorectal cancer. The enhancement of
metabolism in type 2 diabetic patients undergoing elec-
t have provided further explanation for the limited sup-
pression of endogenous glucose production by glucose
in the diabetic patients.

In summary, this study presents the first integrated
analysis of postoperative changes in protein and glucose
metabolism in type 2 diabetic patients undergoing elec-
tive resections of colorectal cancer. The enhancement of
postoperative protein oxidation in diabetic patients most
likely indicates an increased catabolic response to sur-
gery, whereas the alterations in glucose metabolism can be
at least in part attributed to changes induced by
diabetes mellitus per se.

The authors thank the nursing staff of the Department of Surgery, Royal
Victoria Hospital, McGill University, Montreal, Canada, for their help in
the execution of the experiments.

References

1. Frayn KN: Hormonal control of metabolism in trauma and sepsis. Clin
Endocrinol 1986; 24:577–99
2. Simmons PS, Miles JM, Gerich JE, Hayward MW: Increased proteolysis: An
effect of increases in plasma cortisol within the physiological range. J Clin Invest
1984; 73:412–20
J Clin Invest 1980; 65:717–21
4. Woolfson A, Heatley R, Allison S: Insulin to inhibit protein catabolism after
5. Richardson AP, Tayek JA: Type 2 diabetic patients may have a mild form of
an injury response: A clinical research center study. Am J Physiol 2002; 282:
E1286–90
Philadelphia, Saunders, 1993, pp 649–66
7. Barker JP, Robinson PN, Vafidis GC, Burrin JM, Sapsed-Byrne S, Hall GM:
Metabolic control of non-insulin-dependent diabetic patients undergoing cataract
8. Carli F, Webster J, Halliday D: A nitrogen-free hypocaloric diet and recom-
binant human growth hormone stimulate postoperative protein synthesis. Fasted
and fed leucine kinetics in the surgical patient. Metabolism 1997; 46:796–800
9. Frayn K: Calculation of substrate oxidation rates in vivo from gaseous
10. Ang B, Wade A, Halliday D, Powell-Tuck J: Insulin reduces leucine oxida-
tion and improves net leucine retention in parenterally fed humans. Nutrition
2000; 16:221–5
11. Mamer OA, Montgomery JA: Determination of branched-chain 2-hydroxy
13. Gougeon R: The metabolic response to two very low energy diets (VLED)
16:105–12
14. Schwenk WF, Beaurefrre B, Hayward MW: Use of reciprocal pool specific
activities to model leucine metabolism in humans. J Am Physiol 1985; 249:
E646–50
15. Matthews D, Motil K, Rohrbaugh D, Burke J, Young V, Bier D: Measure-
ment of leucine metabolism in man from a primed, continuous infusion of
protein and glucose metabolism during surgery: effects of anesthesia. J Appl
Physiol 2003; 95:2525–30
17. Shamon M, Hendler R, Sherwin R: Altered responsiveness to cortisol,
epinephrine, and glucagon in insulin-infused juvenile-onset diabetes: A mecha-
18. Charlton MR, Nair KS: Role of hyperglycaemia in catabolism associated
with type I diabetes: Effects on leucine metabolism and the resting metabolic
19. Inchiostro S, Biolo G, Bruttomesso D, Fongher C, Sahabid L, Carlini M,
Duner T, Tiengo A, Tessari P: Effects of insulin and amino acid infusion on leucine
20. Luzi L, Petrides AS, Defronzo RA: Different sensitivity of glucose and
amino acid metabolism to insulin in NIDDM. Diabetes 1993; 42:1868–77
21. Umpfeley AM, Scobie IN, Borujiarend JA, Carson ER, Sonksen PH: Diurnal
variations of glucose and leucine metabolism in non-insulin-dependent diabetes.
proteins, muscle functions, and amino acid kinetics in type 2 diabetes.
Diabetes 2002; 51:2395–404
effect on leucine kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab 2002;
15:136–42
24. Gougeon R, Pencharz PB, Sigal RJ: Effect of glycemic control on the
kinetics of whole-body protein metabolism in obese subjects with non-
dependent diabetes mellitus during iso- and hypoglycemic feeding. Am J Clin
Nutr 1997; 65:861–70
25. Gougeon R, Raffl Be, Jones PJ, Pencharz PB, Morais JA: Effect of exog-
ous coenzyme Q10 on protein metabolism with differing energy intake levels in
26. Stamen MA, Matthews DE, Bier DM: Leucine metabolism in type 2 diabetes
27. Magnusson J, Rothman DL, Katz LD, Shulman RG, Shulman GI: Increased
rate of gluconeogenesis in type II diabetes mellitus: A 13C nuclear magnetic
28. Basu R, Schwenk WF, Rizza RA: Both fasting glucose production and
disappearance are abnormal in people with “mild” and “severe” type 2 diabetes.
30. Honeycombe DA, Shaw JHF: Metabolism in hemotologic malignancy.
exchange of blood-borne amino acids in the leg during abdominal surgical trauma:
32. Schricker T, Klibien K, Wykes L, Carlil F: Effect of epidural blockade on
protein, glucose, and lipid metabolism in the fasted state and during dextrose
infusion in volunteers. Anesthesiology 2000; 92:62–9
33. Pozefsky T, Felig P, Tobin JD, Soeldner JS, Cahill GF: Amino acid balance
across tissues of the forearm in postbarbiturate man: Effects of insulin at two dose
34. Elia M, Neale G, Livesey GA: Alanine and glutamine release from the human
35. Shaw JHF, Klein S, Wolfe RR: Assessment of alanine, urea and glucose
metabolism in normal subjects and in patients with sepsis with stable
36. Shaw JHF, Wolfe RR: An integrated analysis of glucose, fat, and protein
Contribution of elevated free fatty acid levels to the lack of glucose effectiveness
38. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L:
Regulation of endogenous glucose production by glucose per se is impaired in
Impaired basal glucose effectiveness in NIDDM: Contribution of defects in
glucose disappearance and production, measured using an optimized minimal
40. Heise T, Heinemann L, Starke AR: Simulated postaggression metabolism in
healthy subjects: Metabolic changes and insulin resistance. Metabolism 1998;
47:1263–8